An accomplished pharmaceutical executive and strategic business leader, Dr. Gordon has extensive experience in the development of drugs from first in-human studies to approval and commercialization.
Dr. Gordon brings innovative approaches to the process, leveraging advantageous regulatory pathways and close collaborations with investigators, patient advocacy groups and key academic and government consortiums.
Prior to joining GCAR, Dr. Gordon served as Vice President, Oncology Department at AbbVie (a spin-off of Abbott), where he oversaw the development of AbbVie’s oncology projects. He played a critical role in the oncology business expansion, leading to AbbVie’s current position in Oncology. This includes the approval of venetoclax, several major acquisitions and other collaborations. Dr. Gordon was on the AbbVie-Genentech team that received the 2017 Prix Galien award for the Best Pharmaceutical Product.
Prior to AbbVie, Dr. Gordon was Chief Scientific Officer and Vice President of Clinical Affairs at Ovation Pharmaceuticals from 2001 to 2003.
Dr. Gordon entered the pharmaceutical industry in 1995, joining the G.D. Searle division of Monsanto, which eventually became part of Pharmacia.
